Clinical review report: Lanadelumab (Takhzyro) (Shire pharma Canada ULC) indication : for routine prevention of attacks of hereditary angioedema in adolescents and adults
The objective of this review is to evaluate the beneficial and harmful effects of lanadelumab for the routine prevention of attacks of hereditary angioedema in adolescents and adults
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, January 2020
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references